Becton Dickinson Net Change in Short-term Investments 2010-2024 | BDX
Becton Dickinson annual/quarterly net change in short-term investments history and growth rate from 2010 to 2024. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Becton Dickinson net change in short-term investments for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Becton Dickinson net change in short-term investments for the twelve months ending December 31, 2024 was $-0.815B, a 0% increase year-over-year.
- Becton Dickinson annual net change in short-term investments for 2024 was $0B, a 0% decline from 2023.
- Becton Dickinson annual net change in short-term investments for 2023 was $0B, a 0% decline from 2022.
- Becton Dickinson annual net change in short-term investments for 2022 was $0B, a 0% decline from 2021.
Becton Dickinson Annual Net Change in Short-term Investments
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$-1 |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$-225 |
| 2012 |
$-138 |
| 2011 |
$122 |
| 2010 |
$35 |
| 2009 |
$-338 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$50.254B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
